227 related articles for article (PubMed ID: 10767388)
21. Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma.
Dursun BA; Memiş L; Dursun A; Bayiz H; Ozkul M
Pathol Oncol Res; 1999; 5(4):285-90. PubMed ID: 10607923
[TBL] [Abstract][Full Text] [Related]
22. Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance.
Jassem E; Bigda J; Dziadziuszko R; Schlichtholz B; Le Roux D; Grodzki T; Rzyman W; Konopa K; Poberezna M; Dobrzańska Z; Skokowski J; Soussi T; Jassem J
Lung Cancer; 2001 Jan; 31(1):17-23. PubMed ID: 11162862
[TBL] [Abstract][Full Text] [Related]
23. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer.
Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A
Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907
[TBL] [Abstract][Full Text] [Related]
24. An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.
Wu WB; Yie SM; Ye SR; Xie K; Zhang JB; Cao M; Chen J; He X; Ma XL; Zhang J
Ann Thorac Surg; 2018 Jun; 105(6):1664-1670. PubMed ID: 29453962
[TBL] [Abstract][Full Text] [Related]
25. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J
Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076
[TBL] [Abstract][Full Text] [Related]
26. Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation.
Segawa Y; Takigawa N; Mandai K; Maeda Y; Takata I; Fujimoto N; Jinno K
Lung Cancer; 1997 Mar; 16(2-3):229-38. PubMed ID: 9152954
[TBL] [Abstract][Full Text] [Related]
27. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum levels of soluble interleukin-2 receptors in small cell lung carcinoma.
Yamaguchi K; Nishimura Y; Kiyokawa T; Matsuzaki H; Ishii T; Kubota K; Kawahara M; Furuse K; Yoshinaga T; Kinuwaki E
J Lab Clin Med; 1990 Oct; 116(4):457-61. PubMed ID: 2170552
[TBL] [Abstract][Full Text] [Related]
29. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.
Steels E; Paesmans M; Berghmans T; Branle F; Lemaitre F; Mascaux C; Meert AP; Vallot F; Lafitte JJ; Sculier JP
Eur Respir J; 2001 Oct; 18(4):705-19. PubMed ID: 11716177
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of serum p53 antibodies in lung cancer.
Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
[TBL] [Abstract][Full Text] [Related]
31. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
33. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.
Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O
Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456
[TBL] [Abstract][Full Text] [Related]
34. Lymphocyte subsets in lung cancer.
Wesselius LJ; Wheaton DL; Manahan-Wahl LJ; Sherard SL; Taylor SA; Abdou NA
Chest; 1987 May; 91(5):725-9. PubMed ID: 3032522
[TBL] [Abstract][Full Text] [Related]
35. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
[TBL] [Abstract][Full Text] [Related]
36. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
37. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition.
Sculier JP; Chansky K; Crowley JJ; Van Meerbeeck J; Goldstraw P;
J Thorac Oncol; 2008 May; 3(5):457-66. PubMed ID: 18448996
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
39. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
Chen SS; Li K; Wu J; Peng ZY; Wang ZD; Wang JC; Xu CW; Zhu CL; Li BC; Ren H; Tang SC; Sun X
J Cancer Res Clin Oncol; 2021 Jan; 147(1):223-233. PubMed ID: 32691153
[TBL] [Abstract][Full Text] [Related]
40. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.
Hirasawa Y; Kohno N; Yokoyama A; Kondo K; Hiwada K; Miyake M
Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):589-94. PubMed ID: 10673204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
